On 12 January 2017, orphan designation (EU/3/16/1810) was granted by the European Commission to ProMetic Pharma SMT Limited, United Kingdom, for 3-pentylbenzeneacetic acid sodium salt for the treatment of Alström syndrome.
3-pentylbenzeneacetic acid sodium salt
|Disease / condition||
Treatment of Alström syndrome
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.